Replies to post #169074 on Biotech Values

[DewDiligence]

As a MNTA long, I’ll be content if annualized US Copaxone sales in May 2014 are still in the neighborhood of $3B. Based on the 3Q13 number ($798M) and the likelihood of another Copaxone price increase in January, the chances look pretty good.